<DOC>
	<DOC>NCT00030186</DOC>
	<brief_summary>The purpose of this study is to determine the response rate of patients with refractory, relapsed or poor risk AML expressing FLT-3 activating mutations, when administered CEP-701 at a dosage of 60 mg 2 times a day.</brief_summary>
	<brief_title>Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation</brief_title>
	<detailed_description>This is an open-label study of CEP-701 in patients with refractory, relapsed, or poor risk AML expressing FLT-3 activating mutations. Patients who meet eligibility criteria will be enrolled at a dosage of 60 mg orally 2 times a day for 28 days (1 cycle). Upon completion of cycle 1, the dosage may be increased to 80mg 2 times a day or decreased to 40 mg 2 times a day, dependent upon response to 60 mg dosage.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<criteria>INCLUSION CRITERIA: patient must have confirmed diagnosis of refractory or relapsed AML that expresses a FLT3 mutation patient must have life expectancy of more than 2 months patient must be fully recovered from reversible side effects of previous therapy for cancer EXCLUSION CRITERIA: total bilirubin, ALT or AST greater than 2 times upper limit of normal patient &lt;65 years of age with estimated creatinine clearance less than 60 mL/min; patient &gt;65 years of age with serum creatinine &gt; 1.5 times the upper limit of normal (ULN) received any investigational drug within past 4 weeks GI disturbance/malabsorption that may affect absorption of CEP701 HIV positive received NSAID within prior 14 days has active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>AML</keyword>
	<keyword>FLT-3 mutation</keyword>
</DOC>